Gracell Biotech, a Suzhhou company developing novel CAR-T therapies, was approved to start a China Phase I/II clinical trial of its allogeneic donor-derived CD19 CAR-T cell therapy. GC007g will be tested in patients with B-cell acute lymphoblastic leukemia (B-ALL). It will be administered to B-ALL patients who relapsed after receiving an allogeneic transplant and are not eligible for autologous CAR-T therapy because of compromised T-cells. Gracell said the seamless, potentially pivotal Phase I/II clinical trial of GC007g will accelerate clinical development of GC007g . More details.... Stock Symbol: (NSDQ: GRCL) Share this with colleagues: // //